Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapy

• Published in: Electrophoresis Vol. 33; no. 13; pp. 1975 - 1979
• Main Authors: Shayan, Gilda, Adamiak, Basia, Relkin, Norman R., Lee, Kelvin H.
• Format: Journal Article
• Language: English
• Published: Germany Blackwell Publishing Ltd 01.07.2012
• Subjects: Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - therapy; Alzheimer's disease; biomarkers; Biomarkers - cerebrospinal fluid; Cerebrospinal fluid; Classification; Clinical trials; Decision Trees; Drugs; Electrophoresis, Gel, Two-Dimensional; Forests; Humans; Immunoglobulins; Immunoglobulins, Intravenous - therapeutic use; Immunotherapy; Intravenous administration; IVIg; Longitudinal Studies; Neurodegenerative diseases; Proteome - analysis; Proteomics; Random forest; Reversion; Therapeutic applications
• ISSN: 0173-0835; 1522-2683; 1862-8346; 1522-2683
• DOI: 10.1002/elps.201100660

Intravenous immunoglobulin (IVIg) therapy has shown promising results in treating Alzheimer's disease (AD). In this study, a Random Forest (RF) classification model was used to identify possible effects of IVIg on a group of eight subjects who underwent immunotherapy. Cerebrospinal fluid (CSF) samples from eight ADsubjects who underwent IVIg therapy were collected before therapy, after 6 months of therapy, and after a 3‐month drug washout period. Samples were analyzed using 2DE and further studied using a RF classification model to identify effects of IVIg on a panel of 23 putative diagnostic ADbiomarkers previously identified. Six of the eight subjects showed improvements with respect to the 23 ADdiagnostic biomarkers after 6 months of therapy compared to the samples taken at the outset of the trial. All subjects reverted back to baseline during drug washout. These results are also consistent with clinical observations. The observed improvements in subjects during 6 months of IVIg therapy and the reversion back to baseline during drug washout provides preliminary evidence regarding the potential use of IVIg as an AD immunotherapy.